Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Colorcon
Baxter
Teva
UBS
QuintilesIMS
Covington
Express Scripts

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020741

« Back to Dashboard

NDA 020741 describes PRANDIN, which is a drug marketed by Gemini Labs Llc and is included in one NDA. It is available from four suppliers. Additional details are available on the PRANDIN profile page.

The generic ingredient in PRANDIN is repaglinide. There are sixteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the repaglinide profile page.
Summary for 020741
Tradename:PRANDIN
Applicant:Gemini Labs Llc
Ingredient:repaglinide
Patents:0
Therapeutic Class:Blood Glucose Regulators
Formulation / Manufacturing:see details
Pharmacology for NDA: 020741
Mechanism of ActionPotassium Channel Antagonists
Suppliers and Packaging for NDA: 020741
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PRANDIN repaglinide TABLET;ORAL 020741 NDA Novo Nordisk 0169-0081 N 0169-0081-80
PRANDIN repaglinide TABLET;ORAL 020741 NDA Novo Nordisk 0169-0081 N 0169-0081-81

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.5MG
Approval Date:Dec 22, 1997TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:Dec 22, 1997TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Dec 22, 1997TE:ABRLD:Yes

Expired US Patents for NDA 020741

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Deloitte
Chinese Patent Office
Healthtrust
McKesson
AstraZeneca
Moodys
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.